Pune-based Gennova Biopharmaceuticals, a subsidiary of Emcure Pharma, is set to soon start phase-2 and 3 trials of India’s first mRNA based vaccine for Covid-19. “They have got regulatory approvals and the last-stage trials are expected to start soon. The company will soon start enrolment for the trials,” said a senior government official.

The study will be conducted at 10-15 sites in phase-2 and 22-27 sites in phase-3. To assess the immunogenicity of the mRNA vaccine, Gennova will have to use Covishield — an existing vaccine — as a comparator, as the regulator has disallowed use of a placebo for the trials.
https://economictimes.indiatimes.com/industry/healthcare/biotech/ph...